200 related articles for article (PubMed ID: 8031876)
1. Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation.
Chamow SM; Kogan TP; Venuti M; Gadek T; Harris RJ; Peers DH; Mordenti J; Shak S; Ashkenazi A
Bioconjug Chem; 1994; 5(2):133-40. PubMed ID: 8031876
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of a CD4 immunoadhesin.
Byrn RA; Mordenti J; Lucas C; Smith D; Marsters SA; Johnson JS; Cossum P; Chamow SM; Wurm FM; Gregory T; Groopman JE; Capon DJ
Nature; 1990 Apr; 344(6267):667-70. PubMed ID: 1970124
[TBL] [Abstract][Full Text] [Related]
3. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin.
Ward RH; Capon DJ; Jett CM; Murthy KK; Mordenti J; Lucas C; Frie SW; Prince AM; Green JD; Eichberg JW
Nature; 1991 Aug; 352(6334):434-6. PubMed ID: 1907354
[TBL] [Abstract][Full Text] [Related]
4. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG).
Flasher D; Konopka K; Chamow SM; Dazin P; Ashkenazi A; Pretzer E; Düzgünes N
Biochim Biophys Acta; 1994 Aug; 1194(1):185-96. PubMed ID: 8075135
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments.
Chamow SM; Peers DH; Byrn RA; Mulkerrin MG; Harris RJ; Wang WC; Bjorkman PJ; Capon DJ; Ashkenazi A
Biochemistry; 1990 Oct; 29(42):9885-91. PubMed ID: 2125484
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of a recombinant CD4-IgG hybrid molecule.
Harris RJ; Wagner KL; Spellman MW
Eur J Biochem; 1990 Dec; 194(2):611-20. PubMed ID: 2269286
[TBL] [Abstract][Full Text] [Related]
7. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382
[TBL] [Abstract][Full Text] [Related]
8. Immunoadhesins as research tools and therapeutic agents.
Ashkenazi A; Chamow SM
Curr Opin Immunol; 1997 Apr; 9(2):195-200. PubMed ID: 9099788
[TBL] [Abstract][Full Text] [Related]
9. CD4 immunoadhesins in anti-HIV therapy: new developments.
Chamow SM; Duliege AM; Ammann A; Kahn JO; Allen JD; Eichberg JW; Byrn RA; Capon DJ; Ward RH; Ashkenazi A
Int J Cancer Suppl; 1992; 7():69-72. PubMed ID: 1428410
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice.
Sanhadji K; Grave L; Touraine JL; Leissner P; Rouzioux C; Firouzi R; Kehrli L; Tardy JC; Mehtali M
AIDS; 2000 Dec; 14(18):2813-22. PubMed ID: 11153662
[TBL] [Abstract][Full Text] [Related]
11. CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1.
Berkower I; Mostowski H; Bull TE; Murphy D
J Infect Dis; 1996 Apr; 173(4):863-9. PubMed ID: 8603964
[TBL] [Abstract][Full Text] [Related]
12. SAXS data analysis and modeling of tetravalent neutralizing antibody CD4-IgG2 -/+ HIV-1 gp120 revealed that first two gp120 bind to the same Fab arm.
Rathore YS; Solanki AK; Dhoke RR; Ashish
Biochem Biophys Res Commun; 2011 Dec; 415(4):680-5. PubMed ID: 22079291
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
Williamson MP; McCormick TG; Nance CL; Shearer WT
J Allergy Clin Immunol; 2006 Dec; 118(6):1369-74. PubMed ID: 17157668
[TBL] [Abstract][Full Text] [Related]
14. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
[TBL] [Abstract][Full Text] [Related]
15. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.
Vu JR; Fouts T; Bobb K; Burns J; McDermott B; Israel DI; Godfrey K; DeVico A
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):477-90. PubMed ID: 16796521
[TBL] [Abstract][Full Text] [Related]
16. Surface modification of enzymes for therapeutic use: monomethoxypoly (ethylene glycol) derivatization of ribonuclease.
Schiavon O; Caliceti P; Sartore L; Veronese FM
Farmaco; 1991; 46(7-8):967-78. PubMed ID: 1724369
[TBL] [Abstract][Full Text] [Related]
17. PEGylation enhances the therapeutic potential of peptide antagonists of the neonatal Fc receptor, FcRn.
Mezo AR; Low SC; Hoehn T; Palmieri H
Bioorg Med Chem Lett; 2011 Nov; 21(21):6332-5. PubMed ID: 21920737
[TBL] [Abstract][Full Text] [Related]
18. Human IgE receptor alpha-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo.
Haak-Frendscho M; Ridgway J; Shields R; Robbins K; Gorman C; Jardieu P
J Immunol; 1993 Jul; 151(1):351-8. PubMed ID: 7686940
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of six-arm star poly(delta-valerolactone)-block-methoxy poly(ethylene glycol) copolymers.
Zeng F; Lee H; Chidiac M; Allen C
Biomacromolecules; 2005; 6(4):2140-9. PubMed ID: 16004456
[TBL] [Abstract][Full Text] [Related]
20. Blockade of immunoregulatory Fc-signalling by HIV peptides: oligopeptides from HIV gp120 and gp41 bind the Fc portion of IgG and increase the in vitro anti-ssDNA response.
Rahimpour R; Anderson CC; Sinclair NR
Clin Exp Immunol; 1993 Oct; 94(1):26-31. PubMed ID: 8403512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
